Moreover, high prevalence ofchronic pain diseases is expected to foster the growth of PhenylalanineMarket over the forecast period. For instance, according to the AmericanAcademy of Pain Medicine (AAPM), in 2011, around 1.8 billion people sufferedfrom chronic pain. Moreover, the National Institutes of Health (NIH) estimatesthat one in 10 people in the U.S. suffer from chronic pain. According to astudy published in the British Medical Journal in 2016, nearly one-third tohalf of the population in the U.K. suffers from chronic pain. Moreover,according to the NIH estimates published in 2015 by the American Pain Society,around 50 million people in the U.S. suffered from chronic pain.
Phenylalanine is essential alphaamino acid, which functions to maintain adequate levels of monoamineneurotransmitters in the brain, thereby maintaining balanced moods. Deficiencyof phenylalanine causes mental confusion, depression, reduced alertness, memoryimpairment, and loss of appetite. Phenylalanine is majorly present in threeforms: D-Phenylalanine, DL-Phenylalanine, and L-Phenylalanine. L-phenylalanineis natural amino acid found in the proteins, while D-Phenylalanine issynthesized form of phenylalanine, produced in laboratory. DL-phenylalanine issynthetic product made of 50% D-phenylalanine and 50% of L-phenylalanine.
L-phenylalanine is an essentialamino acid, which is also an only form of phenylalanine found in proteins.Major dietary sources of L-phenylalanine include meat, fish, eggs, cheese, andmilk. L-phenylalanine and DL-phenylalanine are commonly used to treatdepression, Attention Deficit-Hyperactivity Disorder (ADHD), chronic pain, and askin disease called vitiligo.
The primary function ofphenylalanine is to produce tyrosine, which further gets converted into threekey neurotransmitters: L-dopa, norepinephrine, and epinephrine. As someantidepressants function by increasing levels of norepinephrine, various formsof phenylalanine have been observed as a possible treatment for depression.Furthermore, D-phenylalanine has been found to be effective in the treatment ofchronic pain. It blocks enkephalinase, an enzyme which increases pain levels inthe body.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1828
Phenylalanine Market Drivers
Increasing prevalence of anxietyand depression are responsible for massive consumptions of anti-depressants, inturn promoting global phenylalanine market growth. For instance, according tothe World Health Organization (WHO) data findings, in 2017, over 300 millionpeople of all ages are suffering from depression worldwide, wherein around800,000 people die due to suicide due to anxiety disorders and depression asprime cause. Moreover, according to the National Institute of Mental Health(NIMH), in 2016, an estimated 10.3 million U.S. adults (4.3% of all U.S.adults) aged 18 or older had at least one major depressive episode with severeimpairment. Furthermore, according to the same source, the prevalence of majordepressive cases was higher among adult females (8.5%) as compared to males(4.8%). Furthermore, the prevalence of adults with a major depressive episodewas highest among individuals aged 18-25 (10.9%). The association (NIMH) alsomentions that these disorders are highly treatable thereby propellingopportunities for growth of the global phenylalanine market.
Furthermore, increasingprevalence of pain and chronic diseases such as cancer and others are drivinggrowth of the phenylalanine market. For instance, according to the NationalCancer Institute, in 2018, around 1,735,350 new cases of cancer are expected tobe diagnosed in the U.S. and 609,640 people are expected to die from thedisease.
Phenylalanine Market Restraints
Phenylalanine should be avoidedin people with certain inherited disorders such as Phenylketonuria (PKU), wherebody build up too much phenylalanine. People with phenylketonuria can developmental retardation, high blood pressure, stroke, and many other serious healthissues if they consume phenylalanine. PKU is severe disorder due to whichinfants are generally screened at birth to determine whether they have thedisorder and will need a special diet to avoid these problems.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/phenylalanine-market-1828
Phenylalanine Market – RegionalAnalysis
Geographically, the globalphenylalanine market is segmented into North America, Latin America, Europe,Middle East, Asia Pacific, and Africa. Increasing incidence of cancer andrising number of trauma cases worldwide is propelling demand for painmanagement associated with it. North America phenylalanine market is expectedto witness significant growth during the forecast period. As per statisticspublished by Centers for Disease Control and Prevention (CDC), in 2014, traumaaccounts for 41 million visits to the emergency ward each year in the U.S.
Furthermore, developed economiessuch as the U.S., U.K. and Germany experience high rate of adoption due tobetter healthcare facilities and easy availability of depression medication inthese countries. According to the American academy of pain medicine, everyyear, over 100 million people suffer from chronic pain, 25.8 million from diabetes,16.3 million from coronary heart disease, and 11.9 million from cancer in theU.S. This number is expected to further increase in the near future.
Increasing research anddevelopment initiatives by various government and non-governmental organizationssuch as National Institutes of Health (NIH) Brain Research through AdvancingInnovative Neurotechnologies (BRAIN), which aims to better understand the humanbrain and harness the same for various therapeutic applications, includingeffective pain management, is expected to create a conducive environment formarket growth in these region.
Phenylalanine Market – Competitor
Some of the key players operatingin the phenylalanine market include Amazing Nutrition, LiftMode (SynaptentLLC), NutraMarks, Inc., NOW foods, healthvit, and Shijiazhuang JirongPharmaceutical Co., Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1828
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
